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Background: Ocular involvement can occur at any stage of syphilis. Prompt diagnosis and 
proper treatment of ocular syphilis are vital to avoid long-term consequences.  
Objectives: To describe the risk factors for ocular syphilis and clinical features of blindness 
caused by syphilis. 
Methods: We report risk factors for ocular syphilis amongst patients seen at the Shanghai Skin 
Disease Hospital between October 2009 to October 2017. We identify patients with ocular 
syphilis resulting in blindness and report the clinical characteristics, laboratory findings and 
treatment outcomes of these patients.  
Results: A total of 8310 new cases of syphilis were seen, of which 213 patients had ocular 
disease and 50 patients had blindness due to syphilis. Increasing age and higher RPR titers were 
associated with ocular involvement but there was no association with HIV status. Blindness in 
syphilis was restricted predominantly to patients with optic nerve involvement and not patients 
with isolated uveitis. Fifty patients (and a total of 67 eyes) met the WHO definition of blindness 
prior to treatment for syphilis. At the end of follow-up vision had improved in 24 of 67 eyes 
(35.8%) after treatment. Successful treatment of uveitis was associated with the best 
improvement in visual acuity, whilst patient with underlying optic atrophy prior to treatment had 
the worst visual outcome. 
Conclusions: Ocular involvement is an important manifestation of syphilis which may result in 
blindness. Our data demonstrates outcomes for ocular syphilis are poor if detected late; early 
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Introduction 
Syphilis, caused by Treponema pallidum (TP), remains a major global health problem. China has 
experienced a marked increase in the incidence of syphilis from 0.2 cases per 100,000 in 1993 to 
31.97 cases per 100,000 in 2016.
1,2 
Outside of China, the incidence of syphilis has also increased 
substantially throughout the world in recent years, including many developed countries, 
predominantly among “men who have sex with men” (MSM), many of whom are co-infected 
with the Human immunodeficiency virus (HIV).
3-5
 
Syphilis is a multi-system disease with involvement of nearly every organ system reported.
6
 
Ocular involvement is a particularly well described phenomenon and has been observed in up to 
one third of all HIV co-infected patients with neurosyphilis.
7 
Comparatively, less is known about 
ocular-syphilis in HIV-negative patients. Syphilis is believed to be an uncommon cause of ocular 
inflammation in HIV-negative patients in the post penicillin age and as a consequence delayed 
diagnosis of ocular syphilis is not uncommon in this group.
8-11
 
Ocular involvement can occur at any stage of syphilis in both HIV positive and HIV negative 
individuals. Eye involvement may be asymptomatic or present as an anterior, intermediate, or 
posterior uveitis, a retinal vasculitis, retinitis, optic neuritis, or scleritis.
11
 Uveitis has been the 
most reported presentation and can occur as early as 6 weeks after initial infection.
12,13 
Ocular 
involvement may be the only manifestation of syphilis and, because the wide range of clinical 
presentations, may mimic many eye diseases, can be associated with delayed diagnosis and 
treatment. Delayed recognition and treatment may result in irreversible visual loss.
14
 The most 
common complaint in patients with ocular involvement is blurred or decreased vision
 
but true 
blindness caused by syphilis is rarely reported, especially in immunocompetent patients.
15,16
 
The aim of this study was to describe risk factors for ocular syphilis and clinical features of 
blindness due to syphilis amongst patients seen at the sexually transmitted diseases (STD) clinic 
in Shanghai Skin Disease Hospital. 
 
Methods 
This was a retrospective cohort study which included all patients diagnosed with syphilis seen at 
Shanghai Skin Disease Hospital between October 2009 to October 2017. Enrolled patients 
included those seen because of a skin rash or genital symptoms, patients undergoing routine 
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patients were managed with input from the hospital syphilis multidisciplinary team which 
includes a neurologist, ophthalmologist, dermatologist and physician. For each individual, we 
extracted basic demographic, clinical and laboratory data including age, gender, HIV status, 
rapid plasma reagin (RPR) titer, the clinical stage of syphilis, whether the patient had ocular 
involvement and whether the patient met the World Health Organization (WHO) definition of 
blindness (best-corrected visual acuity of less than 0.05).
17 
The study was approved by the 
Shanghai Skin Disease Hospital Ethics Committee (NO.2016-011).   
In individuals who met the WHO definition of blindness we extracted detailed ocular 
examination data. We also extracted data on care-seeking including the duration and date of 
initial onset of ocular symptoms, first date of seeking medical care, time to seeking medical care, 
number of health care facilities seen before final diagnosis, the duration between onset of 
symptoms and the final diagnosis of ocular syphilis, and any treatment received. All patients 
underwent a complete physical examination and HIV screening regarding previous HIV status 
alongside serological testing for syphilis. Patients with ocular syphilis underwent lumbar 
puncture (LP) for cerebrospinal fluid (CSF) analyses. The diagnosis of ocular syphilis was based 
on positive results of both non-treponemal and treponemal serological tests alongside ocular 
examinations.  
The diagnosis of confirmed neurosyphilis was made on the basis of a reactive CSF- Venereal 
Disease Research Laboratory (VDRL) and CSF- Treponema pallidum particle agglutination 
(TPPA) tests in the absence of substantial contamination of CSF with blood. Presumptive 
neurosyphilis was defined as patients with a nonreactive CSF-VDRL test but reactive CSF-TPPA 
with either or both of the following: (i) CSF protein concentration>45 mg/dl or CSF white blood 
cell (WBC) counts≥8/μl in the absence of other known causes for the abnormalities; (ii) clinical 
neurological or psychiatric manifestations consistent with neurosyphilis without other known 
causes for such abnormalities as previously reported.
18,19 
For the purposes of analyses, we 
categorized RPR as 1:8 or >1:8. For patients without ocular disease we report the stage as early 
(primary and secondary), latent or late (tertiary syphilis). For patients with ocular disease we 
report the stage of syphilis as early (primary and secondary), unknown duration or late (tertiary 
syphilis). For patients meeting the definition of primary or secondary syphilis, with or without 
ocular disease, we report the stage as early. For patients without ocular disease we classify the 
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late-latent syphilis according to the 2018 CDC definitions. For patients meeting the definition of 
tertiary syphilis, with or without ocular disease, we report the stage as late in line with the 2018 
CDC definitions. By definition and unlike patients without ocular disease, no patient with ocular 
syphilis can be classified as having latent infection. As some patients presented with ocular 
disease but without meeting the case definition for primary, secondary or tertiary syphilis we 
classified these patients as having active syphilis of unknown duration. Primary syphilis was 
defined as presence of a chancre accompanied by visualization of spirochetes by dark-field 
microscopic examination or positive RPR and TPPA. Secondary syphilis was classified as 
patients with skin or mucocutaneous lesions and a positive RPR and TPPA. Latent syphilis was 
defined as an asymptomatic individual with a positive RPR and TPPA. Tertiary syphilis was 
defined as an individual with manifestations of late neurosyphilis, cardiovascular syphilis, or 
gummatous syphilis and a positive RPR and TPPA. As the duration of disease was not available 
for all patients with ocular disease, we report only proportions of patients in each category but 
did not include stage of syphilis in our regression model.  
The treatment of ocular syphilis was one of the following: (i)aqueous crystalline pencillin G, 
4MU intravenously every 4h for 14 days;
20
 (ii)ceftriaxone intravenously, 2g daily for 14 days, 
because of allergy to penicillin;
20
 (iii)oral doxycycline (200 mg daily) for 30 days due to allergy 
to both penicillin and cephalosporin.
20,21
 
The best-corrected visual acuity was evaluated using a standard logarithmic visual acuity chart. A 
change of one line indicated visual improvement or worsening. 
Univariable logistic regression was used to identify demographic, clinical and laboratory features 
associated with ocular syphilis and blindness. Variables that appeared to have significant 
association (p<0.1) in the univariable analysis were included in a multivariable logistic 
regression model. We considered age and gender as forced confounders for the purpose of 
logistic regression. Finally, factors with a level at p < 0.05 were considered statistically 
significant in the multivariable logistic regression. All statistical analysis was performed in the R 
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our STD outpatient department. During this period, a total of 2.6% of patients (n = 213) had 
ocular involvement as a manifestation of their syphilis and a total of 0.6% of patients (n = 50) 
had involvement of at least one of their eyes sufficient to meet the definition of blindness. The 
mean age of patients with syphilis was 40.0±14.3 years and the majority were male (61.2%, n = 
5082). Overall the HIV status was known for 60.8% (n = 5050) of patients of whom 3.9% (n = 
199) were HIV positive. Patients with ocular syphilis were older (mean 55.0±11.2 vs 40.3±14.2 
years) than patients without ocular syphilis and were more likely to have an RPR titer >1:8 (85.9% 
vs 48.1%) (Table 1). Of 213 patients with ocular syphilis, 14 (6.6%) patients were MSM and 7 
(3.3%) patients were HIV positive. The most common ocular diagnoses were uveitis（42.3%, n = 
90) and optic neuritis (14.7%, n = 31). 
 
Risk factors for ocular syphilis 
In univariable logistic regression a high RPR titer and increasing age were both associated with a 
significantly increased risk of ocular syphilis, but there was no association with gender (OR 1.0, 
95% CI 0.7 – 1.3, p = 0.821) or HIV status (OR 0.6, 95% CI 0.3 – 1.2, p = 0.142). In 
multivariable regression both a high-titer RPR (aOR 3.2, 95% CI 2.2 - 4.9) and increasing age 
remained associated with a significantly increased risk of ocular disease (Table 2). In univariable 
analysis comparing patients with non-blinding ocular syphilis to patients with blinding ocular 
syphilis there was no association between risk of blinding ocular disease and baseline RPR titer 
(p=0.984), age (p=0.985), gender (p=0.161) or HIV status (p=0.234). Compared to patients with 
uveitis, individuals with optic neuritis had an increased risk of blindness although this did not 
achieve statistical significance (OR 2.2,95% CI:0.8 – 5.7, p = 0.1), whilst individuals with optic 
atrophy had a statistically significantly increased risk of blindness (OR 28.7, 95% CI :10.0 – 97.8, 
p < 0.001). 
 
Ocular manifestations of the 67 eyes with blindness 
In the fifty patients who met the WHO definition of blindness, a total of 99 eyes were affected, 
and 67 eyes were classified as blind (Table 3). Seventeen patients (34.0%) had bilateral blindness, 
while 33 patients (66.0%) had unilateral blindness. Of 33 eyes, which did not meet the WHO 
definition of blindness, visual acuity was also frequently impaired. Amongst patients with 
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neuritis (n = 11), uveitis (n = 10) and retinitis (n = 3). In patients with blinding disease, the 
median time from onset of ocular symptoms to diagnosis was 12 months (Interquartile range 
4-36 months), and the median time from initially seeking care to diagnosis was 9 months 
(Interquartile range 1-18 months) (Supplementary Table 1). Prior to diagnosis, all patients had 
visited an ophthalmologist, and 42 patients were treated by ophthalmologists, including receiving 
oral neurotropic drugs (e.g. mecobalamin tablets), glucocorticoids either orally or by injection, 
topical eye drops, and in some cases referral to surgery (e.g. patients with syphilitic 
chorioretinopathy misdiagnosed as cataract referred to surgery). As expected, no patients had 
improvement in vision with these therapies. Forty (80%) patients had ocular involvement as the 
primary clinical manifestation, whilst seven patients also reported dysesthesias or limb weakness. 
Two patients had findings consistent with syphilitic dementia and one had a rash of secondary 
syphilis.  
A positive CSF-VDRL test was shown in 84.0% patients (n = 42) and the range of CSF-VDRL 
titers was 1:1-1:32. Seven patients had negative CSF-VDRL test but a positive CSF-TPPA test 
and increased total protein (>45 mg/dl) or WBC counts（≥8/μl). Only one case had both a 
negative CSF-VDRL and CSF-TPPA accompanied by a normal CSF total protein and WBC 
counts (Table 3). CSF cultures for bacteria and fungi were negative in all 50 patients. Overall 42 
cases met the diagnostic criteria of neurosyphilis, seven met the criteria for presumptive 
neurosyphilis and one did not meet the criteria for neurosyphilis. 
 
Syphilis treatment and follow-up 
Overall, 43 of the 50 patients with syphilis-associated blindness were treated with aqueous 
crystalline pencillin G, whilst six received ceftriaxone and a single patient was treated with 
doxycycline.
 
Ten patients received adjunctive therapy with corticosteroids, most commonly (n = 
8) prednisone 30mg/d orally. Two patients were treated with pulsed intravenous 
methylprednisolone followed by oral steroids. The median follow-up period after treatment was 
20.7 (range 6-80) months (Table 3). At the end of follow-up, the visual acuity was improved in 
24 of 67 (35.8%) eyes but 9 of these eyes still met the WHO diagnostic criteria of blindness. 
Therefore, 52 eyes were finally classified as having permanent vision loss. Improvement in 
visual acuity following treatment was most common in cases of uveitis (90.9%) and lowest in 
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corticosteroid therapy and improvement in vision. Visual acuity improved in 13 of the 32 eyes 
with non-blinding diseases (40.6%) (Table 3).  
 
Discussion 
In this eight-year retrospective cohort study, we found that the proportion of syphilis patients 
with ocular involvement was 2.6%. Increasing age and higher RPR titers were associated with 
ocular involvement. The most common diagnosis was uveitis whilst optic neuritis and optic 
atrophy were the main causes of blindness and had poor treatment outcomes. 
Though syphilis has increased dramatically in China in recent years, national surveillance data 
on ocular manifestations is not routinely collected by China Centers for Disease Control and 
Prevention (CDC). As a result, the true rate of ocular syphilis in China is unknown. In other 
countries where syphilis is resurgent marked increases in ocular syphilis have also been 
reported.
22 
A review of surveillance data during 2012–2013 from King County, Washington, 
revealed that 4.8% of patients with syphilis reported visual symptoms and 2.7% had objective 
findings consistent with ocular syphilis.
23 
In our study a total of 213（2.6%）patients had ocular 
involvement and 0.6% had at least one eye in which resulted in blindness. The true rate of ocular 
syphilis may be higher than we have reported, because patients with mild visual symptoms may 
not have been detected by either the clinician or the patient themselves. Whilst ocular syphilis is 
a treatable disease if it is diagnosed promptly and treated properly delays can lead to serious 
sequelae including lifelong blindness
24-26
. In the pre-antibiotic era, about 9% to 12% of patients 
with ocular syphilis developed blindness.
27
 Consistent with our findings, post-treatment visual 
acuity was dependent on visual acuity at baseline and delayed treatment with no differences in 
efficacy between treatment regimens.
28
 Visual acuity either improved or remained stable in the 
majority of eyes.
29
 We demonstrated a trend towards increased risk of blindness in patients with 
optic neuritis and a predictable and significantly increased risk associated with optic atrophy 
which may reflect the long duration between symptom onset and diagnosis in this group of 
patients.  
Syphilis can involve almost any eye structure, but posterior uveitis and pan uveitis are reported 
to be the most common manifestations. In keeping with this, the most common diagnosis of 
ocular syphilis was uveitis in our study. Whilst previous research supports evidence of 
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likelihood of causing ocular infections.
30 
In syphilis, optic nerve involvement may be unilateral 
or bilateral and manifest as perineuritis, anterior or retrobulbar optic neuritis or papilledema, and 
may lead to decreased visual acuity including permanent blindness, especially in patients with 
optic atrophy.
31 
Our data suggest the risk of blindness is restricted predominantly to patients with 
optic nerve involvement and not those with isolated uveitis. Syphilis is a relatively rare cause of 
optic atrophy and cannot be easily distinguished from non-syphilitic disease. Of patients with 
blinding disease the majority (80%, n = 40) had no other systemic manifestations. The absence 
of the characteristic findings of ocular syphilis, in particular uveitis, may lead ophthalmologists 
not to consider syphilis as a differential diagnosis, and thus lead to delayed treatment.  
Ocular syphilis is frequently associated with neurosyphilis.
32 
In this study, all patients with 
blindness underwent a LP to allow evaluation of CSF findings. Given the importance of making 
a diagnosis of ocular, oto, or neurosyphilis it is clear that all patients who receive a diagnosis of 
syphilis should be asked screening questions to identify visual, hearing, or neurologic symptoms 
and receive a careful neurologic exam. An immediate ophthalmologic evaluation and CSF 
examination is recommended for patients with syphilis and ocular complaints. In our study the 
proportion of individuals with a positive CSF-VDRL test (84%) was higher than most previously 
published reports (Table 5).
22,29,33 
One reason for this may be the longer duration of illness and 
high proportion of optic nerve involvement compared to other studies. Another reason is that the 
patients in our study were all with blindness. In keeping with national and CDC guidelines
 
our 
study supports the need for CSF analyses and management of patients with ocular syphilis 
according to treatment recommendations for neurosyphilis.
 30, 34-35 
The diagnosis of ocular syphilis is challenging due to lack of pathognomonic findings. In the 
context of the current resurgence of syphilis all patients with uveitis, optic neuritis and optic 
atrophy should be tested for syphilis even though the history may not clearly suggest it as the 
diagnosis.
31
 Conversely, for patients with syphilis, clinicians should pay increased attention to 
whether there are eye symptoms, including decreased vision, visual field defects, floaters, 
redness of the eye or eye pain. In a 35 countries study of syphilitic uveitis, optic neuropathy and 
initial misdiagnosis were both identified risk factors for poor outcomes.
36
 Consistent with this, 
our data highlights the importance of early diagnosis of ocular syphilis to prevent blindness. 
Many patients were left with lifelong blindness likely related to delays in seeking care and 
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seven different hospitals and visited doctors 25 times before a diagnosis of ocular syphilis was 
made.  
The major limitation of this study is its retrospective nature which may have resulted in 
incomplete data, such as on HIV status, or misclassification of patients’ syphilis stage. Despite 
this, the current study is, to our knowledge, the largest reported series cases of blindness caused 
by ocular syphilis reported since the start of the HIV epidemic. In developed countries, most 
recent reports of ocular syphilis, including blindness, have been amongst HIV-positive MSM.
30,32 
By contrast severe visual loss, including blindness, has rarely been reported in 
immunocompetent patients in the post penicillin era.
9 
Unlike most previous series in western 
countries our patients were predominantly heterosexual HIV-negative patients and we did not 
demonstrate an association between HIV and ocular syphilis or blindness. Consistent with other 
studies, increasing age and a high baseline RPR titer however were associated with risk of ocular 
disease (Table 5). 
Lifetime blindness is a tragedy. However, if detected early and treated, there is a good visual 
prognosis for patients with syphilitic optic neuritis and uveitis.
32 
Our data highlight the 
importance of considering syphilis even in patients with isolated ocular symptoms and initiating 
prompt diagnostic testing and treatment to avoid irreversible blindness.  
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Table 1.  Demographics of study participants 
    
Non-Ocular 
Syphilis 
Ocular Syphilis Overall P  
Age (Mean & 
SD) 
  40.3 (14.2) 55 (11.2) 40.6 (14.3) <0.001 
Gender 
Male 4942 (61%) 140 (65.7%) 5082 (61.2%) 
0.188 
Female 3155 (39%) 73 (34.3%) 3228 (38.8%) 
RPR 
<= 1:8 4203 (51.9%) 30 (14.1%) 4233 (50.9%) 
<0.001 
>1:8 3894 (48.1%) 183 (85.9%) 4077 (49.1%) 
HIV 
Positive 192 (2.3%) 7 (3.29%) 199 (2.39%) 
0.748 Negative 4645 (57.4%) 206 (96.7%) 4851 (58.4%) 
Unknown 3260 (40.3%) 0 3260 (39.2%) 
Stage 
Early 3862 (47.7%) 11 (5.2%) 3873 (46.6%) 
<0.001 
Latent 4235 (52.3%) N/A 4235 (51%) 
Active Syphilis of 
Unknown Duration 
N/A 136 (63.8%) 136 (1.6%)) 
Late 0 (0%) 66 (31%) 66 (0.8%) 
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Table 2.  Risk factors for ocular syphilis 
      OR 95% CI pa aOR 95% CI pa 
RPR 
      ≤1:8 
     <0.001 
>1:8 3.4 2.3 – 5.1 <0.001 3.2 2.2 – 4.9 
HIV 
    
  
Negative 
      
Positive 0.6 0.3 - 1.2 0.142 
   
Gender 
      Male 
     0.099 




      ≤30 
     
 31-40 3.3 1.5 – 8.0 
<0.001 
3.7 1.6 – 9.0 
<0.001 
41-50 7.2 3.5 – 16.7 8.1 3.9 – 18.9 
51-60 20.5 10.5 – 42.3 21.6 11.0 – 49.0 
61-70 45.3 22.7 – 103.7 48.1 23.9 – 110.8 
>70 25.6 10.3 – 67.0 30.8 12.2 – 81.6 
a
Likelihood ratio test 
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1 61/M 0.02/ NLP optic atrophy 
dysesthesias and 




2.2/56 1:1/+ Doxycycline0.2g P.O/d *30 d 24 0.02/ NLP 
2 64/F 0.6/ NLP retinitis - 
RPR1:128 
TPPA (+) 
36/48 1:32/+ PCN 24 MUI iv/d *14d 72 0.6/ LP 
3 71/M NLP / NLP optic neuritis - 
RPR1:128 
TPPA (+) 
5.5/40 1:8/+ PCN 24 MUI iv/d *14d 80 LP / LP 
4 54/F LP /0.1 optic neuritis - 
RPR1:128 
TPPA (+) 
53.9/40 1:8/+ PCN 24 MUI iv/d *14d 60 LP /0.1 
5 61/M LP / NLP optic atrophy 
dysesthesias in 
the lower limbs 
RPR1:32 
TPPA (+) 
30.8/52 1:8/+ PCN 24 MUI iv/d *14d 12 LP / NLP 
6 39/M LP /0.04 optic atrophy - 
RPR1:16 
TPPA (+) 
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7 78/M LP / LP optic atrophy mental disorder 
RPR1:512 
TPPA (+) 
105.6/60 1:4/+ PCN 24 MUI iv/d *14d 36 0.5 / LP 
8 70/M NLP / NLP optic atrophy mental disorder 
RPR1:64 
TPPA (+) 
47.3/73 1:4/+ Ceftriaxone 2g iv/d *15d 33 NLP / NLP 




PCN 24 MUI iv/d *14d + 
prednisone 30mg/d orally 
24 NLP /0.8 
10 43/M LP /0.01 optic atrophy - 
RPR1:4 
TPPA (+) 
0/95 1:8/+ PCN 24 MUI iv/d *14d  24 LP /0.01 




PCN 24 MUI iv/d *14d + 
methylprednisolone pulse 
therapy 
15 1.2 / 0.8 
12 56/M LP / NLP optic atrophy 
dysesthesias in 
the left lower limb 
RPR1:32 
TPPA (+) 
10/99 1:8/+ PCN 24 MUI iv/d *14d  24 LP / NLP 




PCN 24 MUI iv/d 
*14d+methylprednisolone 
pulse therapy 
24 0.02/ LP 
14 54/F 0.3/ NLP optic neuritis 
dysesthesias in 




PCN 24 MUI iv/d *14d + 
prednisone 30mg/d orally 
12 0.5 / LP 
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 TPPA (+) 
16 63/M LP / LP optic atrophy - 
RPR1:128 
TPPA (+) 
4/88 1:1/+ PCN 24 MUI iv/d *14d 12 LP / LP 




PCN 24 MUI iv/d *14d + 
prednisone 30mg/d orally 
12 0.12 / LP 
18 57/F NLP / HM uveitis - 
RPR1:128 
TPPA (+) 
140/44 1:4/+ PCN 24 MUI iv/d *14d 9 LP / 0.3 
19 63/M 0.15/ LP uveitis - 
RPR1:512 
TPPA (+) 
24/50 1:2/+ PCN 24 MUI iv/d *14d 11 0.6/ 0.02 
20 59/M LP / 0.12 optic atrophy - 
RPR1:64 
TPPA (+) 
0/61 1:4/+ PCN 24 MUI iv/d *14d 5 LP / 0.12 




PCN 24 MUI iv/d *14d + 
prednisone 30mg/d orally 
12 LP / 0.25 
22 64/M FC/LP optic atrophy - 
RPR1:8 
TPPA (+) 
0/30 1:1/+ PCN 24 MUI iv/d *14d 9 0.02 / HM 
23 39/M 0.4/FC optic neuritis - 
RPR1:128 
TPPA (+) 
2/208 1:2/+ PCN 24 MUI iv/d *14d 22 0.8 / 0.6 
24 31/M 0.6/0.02 optic neuritis - 
RPR1:128 
TPPA (+) 
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25 40/M 0.3/FC optic atrophy - 
RPR1:8 
TPPA (+) 
237/55 1:4/+ PCN 24 MUI iv/d *14d 36 0.3/FC 
26 73/M 0.3/HM optic atrophy - 
RPR1:64 
TPPA (+) 
45/34 1:2/+ Ceftriaxone 2g iv/d *15d 36 0.3/HM 
27 51/M 0.5/0.04 retinitis - 
RPR1:2 
TPPA (+) 
28/45 -/+ PCN 24 MUI iv/d *14d 24 0.5/0.04 






PCN 24 MUI iv/d *14d + 
prednisone 30mg/d orally 
35 0.12/FC 
29 62/M 0.02/0.4 optic atrophy - 
RPR1:16 
TPPA (+) 
13/40 1:2/+ PCN 24 MUI iv/d *14d 24 0.02/0.4 
30 61/F 0.01/0.4 uveitis - 
RPR1:64 
TPPA (+) 
416/67 1:8/+ PCN 24 MUI iv/d *14d 12 0.12/ 1.2 
31 51/F 0.6/0.04 uveitis - 
RPR1:8 
TPPA (+) 
294/27 -/+ PCN 24 MUI iv/d *14d 12 0.8/ 0.8 
32 55/M FC/0.2 uveitis 
dysesthesias in 




PCN 24 MUI iv/d *14d + 
prednisone 30mg/d orally 
16 1.0/ 1.0 
33 48/M 1.2/FC optic neuritis - 
RPR1:32 
TPPA (+) 
0/59 -/+ PCN 24 MUI iv/d *14d 12 1.2/FC 
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TPPA (+) 
35 60/M HM/0.2 optic atrophy - 
RPR1:32 
TPPA (+) 
210/147 1:8/+ PCN 24 MUI iv/d *14d 15 NLP /0.1 
36 32/M 0.5/FC uveitis - 
RPR1:512 
TPPA (+) 
20/57 1:4/+ PCN 24 MUI iv/d *14d 12 0.8/ 0.25 
37 74/M LP/0.25 uveitis - 
RPR1:16 
TPPA (+) 
32/57.4 1:4/+ PCN 24 MUI iv/d *14d 12 LP/0.25 
38 55/M NLP / LP optic atrophy 
dysesthesias and 




4/196 1:2/+ PCN 24 MUI iv/d *14d 12 NLP / LP 




PCN 24 MUI iv/d *14d + 
prednisone 30mg/d orally 
10 0.1/ 0.12 
40 51/M HM/0.2 uveitis - 
RPR1:64 
TPPA (+) 
20/15 1:4/+ PCN 24 MUI iv/d *14d 23 0.3/ 0.3 
41 54/M LP/0.6 optic atrophy - 
RPR1:64 
TPPA (+) 
35.2/32 1:4/+ Ceftriaxone 2g iv/d *15d 44 LP/0.6 
42 56/M NLP /0.4 optic atrophy - 
RPR1:8 
TPPA (+) 
10/62 1:2/+ PCN 24 MUI iv/d *14d 6 NLP /1.0 
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TPPA (+) 
44 42/F 0.02/0.1 optic atrophy - 
RPR1:32 
TPPA (+) 
48/28 -/+ PCN 24 MUI iv/d *14d 12 0.04/0.1 
45 54/F NLP /0.2 optic atrophy - 
RPR1:64 
TPPA (+) 
18/61 1:2/+ PCN 24 MUI iv/d *14d 6 NLP /0.2 
46 46/F FC/0.1 optic atrophy - 
RPR1:16 
TPPA (+) 
10/51 1:8/+ PCN 24 MUI iv/d *14d 6 FC/0.1 




PCN 24 MUI iv/d *14d + 
prednisone 30mg/d orally 
18 0.5/0.5 
48 64/M LP/0.04 optic atrophy - 
RPR1:64 
TPPA (+) 
28/98 1:8/+ PCN 24 MUI iv/d *14d 6 LP/0.04 
49 51/M LP/0.1 optic atrophy - 
RPR1:16 
TPPA (+) 
0/145 1:2/+ Ceftriaxone 2g iv/d *15d 6 LP/0.1 
50 64/M LP/0.5 optic neuritis 




600/157 1:32/+ PCN 24 MUI iv/d *14d 6 LP/0.5 
L: left eye; R: right eye; P: CSF protein mg/dl (<=45); W: CSF WBC count cell μl (0-8);  
PCN: aqueous penicillin G 
RPR: Rapid Plasma Reagin; TPPA: Treponema pallidum particle agglutination; CSF: cerebrospinal fluid; VDRL: venereal disease research laboratory test 
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HM (Hand motion): ability to distinguish if a hand is moving or not in front of the patient's face 
LP (Light perception): ability to perceive any light 
NLP (No light perception): inability to see any light or total blindness 
*Optic atrophy is degeneration of, or damage to the optic nerve. 
Optic neuritis is an inflammation that damages the optic nerve, inside or behind the eyeball. 
Uveitis is inflammation of the uvea. 
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Table 4. Treatment effect of blindness caused by syphilis 
 Blindness Eyes Patients Improvement in vision (eyes) 
Optic atrophy 40 26 5(12.5%) 
Optic neuritis 13 11 7(53.8%) 
Uveitis 11 10 10(90.9%) 
Retinitis 3 3 2(66.7%) 











Table 5. Summary and comparison with previous ocular syphilis studies 
 
NR: result not reported 
a Percentage calculated of males.  
b Percentage calculated of those with CSF analysis performed. 
*Data from 50 cases of blindness. 
  Our Study Moradi A, et al29 Lee SY, et al33 Shen J, et al15 Pratas AC, et al37 Oliver SE, et al22 
Ghanimi Zamli AK, 
et al38 
Research period 2009-2017 1984-2014 2008-2014 2009-2014 2012-2015 2014-2015 2013-2017 
Research location Shanghai, China 
United States of 
America 
Los Angeles Zhejiang，China France North Carolina Malaysia 
Number of ocular syphilis 213 35 16 13 21 63 10 
Blindness patients, % (n) 23% (50) 21% (7) 44% (7) 8% (1) NR 6% (4) 50% (5) 
Mean age, y 55 49 43 50 49 45 70 
Male sex, % (n) 66% (140) 74% (26) 100% (16) 54% (7) 100% (21) 94% (59) 30% (3) 
Known MSM, % (n) a 10% (14) 35% (9) 44% (7) 0% (0) 76% (16) 71% (42) 0% (0) 
Co-infection with HIV, % (n) 3% (7) 54% (19) 63% (10) 8% (1) 29% (6) 56% (35) 0% (0) 
Risk factors for ocular 
syphilis 
Increasing age and 
higher RPR titers 
NR NR NR NR 
Male, aged ≥40 
years, white, infected 
with HIV, and higher 
RPR titer 
NR 
CSF VDRL reactive b 84%* 47% 20% 25% 21% 63% NR 







Chorioretinitis Posterior uveitis Uveitis Posterior uveitis 
Improved vision after 
treatment 
36%* 33% 38% 62% 75% 85% 85% 
